Annexon, Inc.
$6.43
▲
2.61%
2026-04-21 05:19:00
www.annexonbio.com
NMS: ANNX
Explore Annexon, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.05 B
Current Price
$6.43
52W High / Low
$7.18 / $1.4
Stock P/E
—
Book Value
$1.42
Dividend Yield
—
ROCE
-92.11%
ROE
-81.9%
Face Value
—
EPS
$-1.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
96
Beta
1.15
Debt / Equity
12.38
Current Ratio
5.68
Quick Ratio
5.68
Forward P/E
-6.12
Price / Sales
—
Enterprise Value
$726.63 M
EV / EBITDA
-3.39
EV / Revenue
—
Rating
Strong Buy
Target Price
$13.71
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Dyadic International, Inc. | $0.88 | — | $31.88 M | — | -114.18% | -3.98% | $1.35 / $0.65 | $0.03 |
| 2. | Canton Strategic Holdings, Inc. | $3.51 | — | $194.33 M | — | -3.9% | -17.99% | $9.08 / $1.05 | $10.72 |
| 3. | CG Oncology, Inc. | $70.4 | — | $6.2 B | — | -25.08% | -21.67% | $73.56 / $19.47 | $9.33 |
| 4. | Inhibikase Therapeutics, Inc. | $1.81 | — | $238.98 M | — | -30.85% | -36.04% | $2.37 / $1.33 | $1.02 |
| 5. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 6. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 7. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -50.26 M | -57.02 M | -51.73 M | -57.41 M | -52.48 M | — |
| Net Profit | -48.26 M | -54.92 M | -49.16 M | -54.36 M | -48.59 M | — |
| EPS in Rs | -0.3 | -0.34 | -0.31 | -0.34 | -0.3 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -216.41 M | -154.07 M | -143.72 M | -145.6 M |
| Net Profit | -206.69 M | -138.2 M | -134.24 M | -141.95 M |
| EPS in Rs | -1.29 | -0.86 | -0.84 | -0.88 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 277.57 M | 350.07 M | 297.67 M | 285.1 M |
| Total Liabilities | 65.92 M | 56.97 M | 47.12 M | 53.9 M |
| Equity | 211.65 M | 293.11 M | 250.56 M | 231.19 M |
| Current Assets | 242.19 M | 316.46 M | 263.86 M | 248.1 M |
| Current Liabilities | 42.63 M | 30.51 M | 17.93 M | 22.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -186.36 M | -118.01 M | -121.14 M | -116.31 M |
| Investing CF | 190.05 M | -218.8 M | 70.7 M | 58.44 M |
| Financing CF | 108.86 M | 161.21 M | 135.52 M | 122.91 M |
| Free CF | -186.49 M | -118.02 M | -121.33 M | -122.83 M |
| Capex | -0.14 M | -0.01 M | -0.19 M | -6.53 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -2.95% | 5.43% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.